Tissue factor pathway inhibitor (TFPI) activity in uremic patients during hemodialysis

By Cella G.   Vianello A.   Rampin E.   Sbarai A.   Boeri G.   Vertolli U.   Naso A.   Strauss W.E.  

Thrombosis Research, Vol. 81, Iss. 6, 1996-03 ,pp. : 671-677

Elsevier

Access to resources Recommend Favorite

Antagonists of Activated Factor X and Thrombin: Innovative Antithrombotic Agents.

By  

Current Vascular Pharmacology, Vol. 5, Iss. 2, 2007-04 ,pp. : 121-128

Bentham Science Publishers

Access to resources Recommend Favorite

Full-length human tissue factor pathway inhibitor inhibits human activated protein C in the presence of heparin

By Hamamoto T.   Kisiel W.  

Thrombosis Research, Vol. 80, Iss. 4, 1995-11 ,pp. : 291-297

Elsevier

Access to resources Recommend Favorite

Comparison of In Vitro Preconditioning Responses of Isolated Pig and Rabbit Cardiomyocytes: Effects of a Protein Phosphatase Inhibitor, Fostriecin

By Armstrong S.C.   Kao R.   Gao W.   Shivell L.C.   Downey J.M.   Honkanen R.E.   Ganote C.E.  

Journal of Molecular and Cellular Cardiology, Vol. 29, Iss. 11, 1997-11 ,pp. : 3009-3024

Academic Press

Access to resources Recommend Favorite

A case of acquired hemophilia caused by factor VIII inhibitor with rheumatoid arthritis, successfully treated with immunosuppressive treatment and recombinant activated factor VII

By Sato Takeo   Hagiwara Kiyofumi   Chikazoe Junnichi   Nakagawa Yasunori   Akiyama Osamu  

Modern Rheumatology, Vol. 14, Iss. 4, 2004-09 ,pp. : 320-322

Springer Publishing Company

Access to resources Recommend Favorite